340B Controversy: Who Really Benefits from Drug Discounts?

RealPharma: Conversations with Pharma Pathfinders

In this episode, Dr. Na-Ri Oh and Ian Wendt discuss the 340B drug pricing program with guest William Sarraille, a healthcare law expert.

They explore the origins of the program and its intended purpose. However, the program has grown exponentially and is now the second largest drug program in the country. Bill raises concerns about the lack of transparency and accountability in the program, as well as the impact on patients. He argues that the program should focus on delivering value to patients and ensuring that they benefit from the discounts.

The conversation delves into the complexities and challenges of the 340B program, highlighting issues such as the patient definition, transparency, contract pharmacies, and the allocation of funds. The discussion considers the need for a more comprehensive and transparent system that ensures the benefits of the program flow to the patients. They also explore the possibility of implementing a claims data process that provides faster payment and greater certainty for both manufacturers and 340B entities.

The conversation concludes with a reflection on the importance of leadership and collaboration in finding solutions to the program's problems.

Resources:

• William Sarraille on LinkedIn
• HRSA 340B Information
• American Hospital Information (AHA) Fact Sheet
• 340BHealth.org